In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fully-Connected Data Infrastructure Offering Will Support Individualized Cancer Therapies

Executive Summary

A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.

You may also be interested in...



Mining The Deep Tech Seam Of Innovation For Healthtech Gold

Singapore-based SGInnovate has a unique multi stakeholder business model focused on identifying and funding Deep Tech start-ups. CEO Jui Lim now plans to increase the group’s activity in advanced manufacturing and “wetware”  ̶   drugs and diagnostics – as firms increasingly are able to revert to pre-COVID business plans.

Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU

Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel